Lv4
420 积分 2024-02-18 加入
CRESS: improving the assessment of disease activity in Sjögren's syndrome
10天前
已完结
Novel therapies in Sjögren’s disease: A systematic review of the literature
13天前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
27天前
已完结
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma
2个月前
已完结
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
5个月前
已完结
Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review
5个月前
已完结
P3.18.59 Resistance Mechanisms and Sequential Therapies Following 1St Line Lorlatinib in ALK+ NSCLC: A Real-World Study (LORES CTONG2501)
5个月前
已完结
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
6个月前
已完结
Comprehensive management strategies for amivantamab-induced toxicities and review of the literature
7个月前
已完结
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
7个月前
已完结
皖公网安备34019202002308
